Health Outcomes Research in Medicine
Volume 1, Issue 2 , Pages e111-e122 , December 2010

Development and Analysis of Item Response Theory-based Short-form Depression Severity Scales Based on the HDRS and MADRS

  • Dennis A. Revicki, PhD

      Affiliations

    • Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland
    • Corresponding Author InformationCorresponding Author: Dennis A. Revicki, PhD, Center for Health Outcomes Research, United Biosource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814.
    • ,
  • Wen-Hung Chen, PhD

      Affiliations

    • Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland
    • ,
  • Lori Frank, PhD

      Affiliations

    • Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland
    • ,
  • Douglas Feltner, MD

      Affiliations

    • Pfizer, Inc., Ann Arbor, Michigan
    • ,
  • Robert Morlock, PhD

      Affiliations

    • Pfizer, Inc., Ann Arbor, Michigan

References 

  1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62
  2. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742–747
  3. Snaith RP. Present use of the Hamilton Depression Rating Scale: observation on method of assessment in research of depressive disorders. Br J Psychiatry. 1996;168:594–597
  4. Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight?. Am J Psychiatry. 2004;161:2163–2177
  5. Santor DA, Coyne JC. Examining symptom expression as a function of symptom severity: item performance on the Hamilton Rating Scale for Depression. Psychol Assess. 2001;13:127–139
  6. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiatr Scand. 1975;51:161–170
  7. Bech P, Allerup P, Gram L, et al. The Hamilton Depression Scale: evaluation of objectivity using logistic models. Acta Psychiatr Scand. 1981;63:290–299
  8. Bech P, Allerup N, Reisby N, Gram LF. Assessment of symptom change from improvement curves on the Hamilton Depression Scale in trials with antidepressants. Psychopharmacology. 1984;84:276–281
  9. Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Smith RP. A comparison of depression rating scales. Br J Psychiatry. 1982;41:45–49
  10. Maier W, Phillips M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry. 1985;18:114–115
  11. Gibbons RD, Clark DC, Jupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure?. J Psychiatr Res. 1993;27:259–273
  12. Maier W, Phillips M, Gerken A. Dimensions of the Hamilton Depression Scale. [German] Eur Arch Psychiatry Neurol Sci. 1985;234:417–422
  13. Brown C, Schulberg HC, Madonia MJ. Assessing depression in primary care practice with the Beck Depression Inventory and the Hamilton Rating Scale for Depression. Psychol Assess. 1995;7:59–65
  14. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000;34:3–10
  15. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th edn.. Washington, DC: American Psychiatric Association; 2000;
  16. Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389
  17. Davidson J, Turnbull CD, Strickland R, et al. Montogomery-Asberg Depression Rating Scale: reliability and validity. Acta Psychiatr Scand. 1986;74:544–548
  18. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321–326
  19. In:  Fayers P,  Hays R editor. Assessing Quality of Life in Clinical Trials. 2nd edition.. New York: Oxford University Press; 2005;
  20. Reeve BR, Fayers P. Applying item response theory modeling for evaluating questionnaire item and scale properties. In:  Fayers P,  Hays R editor. Assessing Quality of Life in Clinical Trials. 2nd edition.. New York: Oxford University Press; 2005;p. 55–73
  21. In:  Van der Linden WJ,  Hambleton RK editor. Handbook of Modern Item Response Theory. New York: Springer-Velag; 1997;
  22. Samejima F. Estimation of latent trait ability using a response pattern of graded scores. Psychometrika Monogr. 1969;34(4):Pt 2: No. 17
  23. Thissen D, Chen WH, Bock D. MULTILOG. Lincolnwood, IL: Scientific Software International; 2004;
  24. Bjoner JB, Smith KJ, Orlando M, Stone C, Thissen D, Sub X. IRTFIT: A Macro for Item Fit and Local Dependence Tests under IRT Models. Lincoln, RI: QualityMetric Inc.; 2006;
  25. Orlando M, Thissen D. Likelihood-based item-fit indices for dichotomous item response theory models. Appl Psychol Meas. 2000;24:50–64
  26. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334
  27. Santor DA, Ramsay JO. Progress in the technology of measurement: application of item response theory models. Psychol Assess. 1998;10:345–359
  28. Evans KR, Sills T, DeBrota D, Gelwicks S, Engelhardt N, Santor D. An item response theory analysis of the Hamilton Depression Rating Scale using shared data from two pharmaceutical companies. J Psychiatr Res. 2004;38:275–282
  29. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry. 2002;24:43–47
  30. Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol. 1999;14:329–337
  31. Wheatley DP, van Moffaert M, Timmerman L, Kremer CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry. 1998;59(6):306–312
  32. Revicki DA, Sloan J. Practical and philosophical issues surrounding a national item bank: if we build it will they come?. Qual Life Res. 2007;16(Suppl 1):167–174

 This study was supported by Pfizer Inc., Ann Arbor, Michigan and in part by the National Institutes of Health Patient-Reported Outcomes Measurement Information System contract (1U01AR052177), Bethesda, Maryland.

PII: S1877-1319(10)00004-2

doi: 10.1016/j.ehrm.2009.11.001

Health Outcomes Research in Medicine
Volume 1, Issue 2 , Pages e111-e122 , December 2010

Article Tools

* Image Usage & Resolution